NEW YORK, August 6, 2026, 17:13 EDT
- ClearOne finished the session at $9.80, rising 166.3%, with trading volume of 64.5 million shares.
- At Thursday’s close, the notional value of the Cortigent consideration stood at $122.5 million, exceeding Vivani Medical, Inc.’s NASDAQ:VANI market capitalization by 10.8%.
- After the financing round, current ClearOne shareholders are projected to own between 12.7% and 14.4%.
ClearOne, Inc. NASDAQ:CLRO finished Thursday’s session at $9.80. Shares surged 166.3% following the company’s announcement of major merger clearance. Trading volume was approximately 64.5 million shares.
Nasdaq closed its regular session by 17:13 EDT, with after-hours trading continuing until 20:00 EDT. The development is significant as ClearOne has reported a share base of just 2.675 million.
| August 6 trading overview | ClearOne | Vivani Medical |
|---|---|---|
| Price | $9.80 | $1.36 |
| Session move | +166.3% | -1.4% |
| Volume | 64.50 million | 50,611 |
| Market value | About $26.2 million | About $110.5 million |
ClearOne disclosed in its August 5 filing that First Finance controlled 61.3% of voting rights. First Finance approved the issuance of 12.5 million merger shares along with a new incentive plan. The share issuance requires a 20-day waiting period after the information statement is mailed before it takes effect.
The same document voided First Finance warrants on 437,500 shares with a $5 exercise price, eliminating prospective dilution of approximately 16.4% of outstanding shares.
Trading activity hit high levels. On Thursday, volume reached 24.1 times the declared shares outstanding. This amounted to 62.4 times the shares not included in First Finance’s reported stake. The latter figure does not represent an estimate of the public float.
| Share-count comparison | Shares | Investor reference |
|---|---|---|
| Outstanding ClearOne shares | 2.675 million | Reported base amount |
| First Finance’s stake | 1.641 million | 61.3% of voting rights |
| Shares not held by First Finance | 1.034 million | Turnover was 62.4 times this figure |
| August 6 total turnover | 64.497 million | Representing 24.1 times overall shares |
| Cortigent share award | 12.500 million | Equivalent to 4.67 times current share base |
The ratios are calculated using ClearOne’s reported trading volume along with share data disclosed to the SEC. Multiple trades of the same shares may occur during a single session.
The fixed merger consideration provided a less common signal. With 12.5 million shares priced at $9.80 each, the notional value amounted to $122.5 million. This surpassed Vivani’s full market capitalisation by almost $12 million.
| Preliminary value verification | Amount |
|---|---|
| 12.5 million ClearOne shares at $9.80 each | $122.5 million |
| Vivani total value on market | $110.5 million |
| Implied difference | $12.0 million |
| Difference as share of Vivani’s value | 10.8% |
The calculation serves as an example and does not represent a transactional value. Fifty percent of Vivani’s consideration shares are subject to a one-year lock-up period, with the other half restricted for two years. Direct arbitrage comparison is further complicated by financing dilution and closing risk.
Dilution is still a key topic. ClearOne could grant Vivani 12.5 million shares, along with 855,000 shares to advisors. The deal proposes issuing between 2.5 million and 5 million units, each comprising one share and a six-month warrant that can be exercised at $10.
| Stake or equity overhang | Shares | Ownership or effect |
|---|---|---|
| Current ClearOne shareholders | 2.675 million | 16.69% prior to financing; projected between 12.7% and 14.4% post-financing |
| Vivani shares issued | 12.500 million | 77.98% prior to financing; expected to be within 59.4%-67.5% after |
| Shares for advisors | Maximum 855,000 | 5.33% prior to financing |
| Units for financing | 2.5 million-5 million | Each unit includes one share plus a $10 warrant |
| 2026 incentive plan shares | 2.5 million | Future additional equity allowance |
The pre-financing figures do not include financing stakes or subsequent incentive grants. ClearOne’s proxy characterizes the merger share issuance as significant dilution.
ClearOne has ceased production and sales of its previous audiovisual product lines. The company disclosed holding $1.05 million in cash as of March 31. It said in a filing there is significant uncertainty about its capacity to remain a going concern.
Upon announcing the deal, Chairman Eric Robinson highlighted the importance of the upcoming funding. “We anticipate that the planned financing will give the combined company a strong foundation,” he said. ClearOne intends to operate under the Cortigent Holdings name and will use the anticipated ticker CRGT. ClearOne
Conventional analyst coverage offers limited valuation clarity. The monitored services did not display an active consensus price target following Thursday’s rally.
| Analyst-recommendation source | Coverage window | Buy | Hold | Sell | Price target |
|---|---|---|---|---|---|
| MarketBeat/Benzinga feed | Past 12 months | 0 | 0 | 1 | N/A |
| TipRanks | Past three months | 0 | 0 | 0 | N/A |
| StockAnalysis/S&P Global | Currently listed | N/A | N/A | N/A | N/A |
According to MarketBeat, Weiss Ratings issued a Sell recommendation on June 1. TipRanks has not recorded any conventional analyst ratings in the last three months. StockAnalysis reports that both analyst coverage and price targets are not available.
Shares of ClearOne ended trading at $4.08 on July 31. By Thursday, the closing price had risen to $9.80, marking a gain of roughly 140% in that span. Looking ahead to next week, investors are set to monitor developments in mailing, updates on financing arrangements, and Nasdaq’s review process.
Risks persist. The merger is still subject to financing as well as Nasdaq clearance. Cortigent does not generate product revenue at present and requires significant further funding. ClearOne has also issued a warning over its ability to continue as a going concern.
